A new co-innovation lab brings advanced GPUs and AI platforms into pharma R&D, using accelerated computing to cut drug discovery timelines and reshape how medicines are designed and tested.
Nvidia and Eli Lilly are teaming up to build a joint artificial intelligence research lab that could redefine how new medicines are discovered, signaling a deeper push by chipmakers into life sciences. The companies will invest up to $1 billion over five years in a San Francisco Bay Area facility where AI and accelerated computing meet biology and chemistry to compress classic R&D timelines.
The initiative, unveiled at the J.P. Morgan Healthcare Conference, places Nvidia’s AI hardware and software stack including its BioNeMo platform and next-gen Vera Rubin architecture at the core of Lilly’s drug discovery pipeline. The lab will co-locate Nvidia’s model builders and engineers with Lilly’s biologists and chemists to jointly generate and train models capable of exploring vast biological and chemical spaces that are too computationally complex for traditional methods.
Drug discovery traditionally takes nearly a decade and costs billions; AI promises to shorten those cycles and cut costs by automating hypothesis testing, molecular design and optimization. By building a continuous learning system that links AI simulations with physical lab experiments in near real-time, the collaboration aims to create feedback loops where models improve as they ingest new data.
For Nvidia, this is part of a broader strategy to embed its GPUs and AI tools deep into high-value industrial and scientific workflows. Lilly’s existing investments including what it calls the pharmaceutical industry’s most powerful AI supercomputer already leverage thousands of Nvidia chips to train foundation models for biology at scale. This new co-innovation lab expands that footprint and could accelerate adoption of Nvidia’s infrastructure across biotech and healthcare.
Analysts see this partnership as both a commercial opportunity and a competitive differentiator: pharma companies with bespoke AI capabilities may bring therapies to market faster, while Nvidia cements its role beyond consumer and enterprise tech into mission-critical scientific computing. The lab is expected to begin operations in early 2026, with further details including exact site plans and staffing to be disclosed soon.
